Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib alone or with vinorelbine for second-line advanced lung squamous cell carcinoma
ChiCTR1800017614Phase 4Not yet recruiting
- Sponsor
- Anhui Chest Hospital
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib and vinorelbine in Pulmonary squamous cell carcinoma (3 arms), sponsored by Anhui Chest Hospital. Primary endpoint: Progression-free survival. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
anlotinibvinorelbine
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR1800017614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017614.